03 Jan 2023 |
Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients
|
03 Jan 2023 |
ProfoundBio Announces Initiation of First-in-Human Trial for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Receives FDA "Study May Proceed" Letter for PRO1160, a CD70-Directed ADC
|
03 Jan 2023 |
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
|
02 Jan 2023 |
Alteogen Enters Into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled by Alteogen’s Hybrozyme™ Technology
|
02 Jan 2023 |
Alligator Bioscience Announces Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate
|
29 Dec 2022 |
TransCode Therapeutics Announces FDA Authorization to Proceed with First-In-Human Clinical Trial
|
29 Dec 2022 |
Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults
|
29 Dec 2022 |
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate
|
28 Dec 2022 |
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors
|
28 Dec 2022 |
Deka Biosciences, Inc Announces Submission of Investigational New Drug (IND) Application for Lead Oncology Asset, DK210 (EGFR)
|
28 Dec 2022 |
PeptiDream Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Peptide Drug Conjugates
|
28 Dec 2022 |
PeptiDream Announces New Research and Collaboration Agreement with Lilly for the Discovery of Novel Peptide Drug Conjugates
|
28 Dec 2022 |
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
|
28 Dec 2022 |
U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
|
28 Dec 2022 |
TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)
|
27 Dec 2022 |
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
|
24 Dec 2022 |
Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
|
24 Dec 2022 |
LegoChem Biosciences and Amgen Enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates
|
24 Dec 2022 |
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
|
23 Dec 2022 |
UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab
|